» Articles » PMID: 10490031

Structures of a Histone Deacetylase Homologue Bound to the TSA and SAHA Inhibitors

Overview
Journal Nature
Specialty Science
Date 1999 Sep 18
PMID 10490031
Citations 488
Authors
Affiliations
Soon will be listed here.
Abstract

Histone deacetylases (HDACs) mediate changes in nucleosome conformation and are important in the regulation of gene expression. HDACs are involved in cell-cycle progression and differentiation, and their deregulation is associated with several cancers. HDAC inhibitors, such as trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA), have anti-tumour effects, as they can inhibit cell growth, induce terminal differentiation and prevent the formation of tumours in mice models, and they are effective in the treatment of promyelocytic leukemia. Here we describe the structure of the histone deacetylase catalytic core, as revealed by the crystal structure of a homologue from the hyperthermophilic bacterium Aquifex aeolicus, that shares 35.2% identity with human HDAC1 over 375 residues, deacetylates histones in vitro and is inhibited by TSA and SAHA. The deacetylase, deacetylase-TSA and deacetylase-SAHA structures reveal an active site consisting of a tubular pocket, a zinc-binding site and two Asp-His charge-relay systems, and establish the mechanism of HDAC inhibition. The residues that make up the active site and contact the inhibitors are conserved across the HDAC family. These structures also suggest a mechanism for the deacetylation reaction and provide a framework for the further development of HDAC inhibitors as antitumour agents.

Citing Articles

Class I histone deacetylases catalyze lysine lactylation.

Tsusaka T, Najar M, Sharma I, Marcinkiewicz M, Crispim C, Snyder N bioRxiv. 2025; .

PMID: 40060688 PMC: 11888385. DOI: 10.1101/2025.02.25.640220.


The histone deacetylase inhibitor Scriptaid targets G-quadruplexes.

Sanchez-Martin V, Ruzic D, Tello-Lopez M, Ortiz-Morales A, Murciano-Calles J, Soriano M Open Biol. 2025; 15(2):240183.

PMID: 39965659 PMC: 11835489. DOI: 10.1098/rsob.240183.


Prodrugs in Oncology: Bioactivation and Impact on Therapeutic Efficacy and Toxicity.

Kurian R, Wang H Int J Mol Sci. 2025; 26(3).

PMID: 39940757 PMC: 11816641. DOI: 10.3390/ijms26030988.


UM171 glues asymmetric CRL3-HDAC1/2 assembly to degrade CoREST corepressors.

Yeo M, Zhang O, Xie X, Nam E, Payne N, Gosavi P Nature. 2025; 639(8053):232-240.

PMID: 39939761 PMC: 11882444. DOI: 10.1038/s41586-024-08532-4.


Control of metalloenzyme activity using photopharmacophores.

Mafy N, Hudson D, Que E Coord Chem Rev. 2025; 499.

PMID: 39822771 PMC: 11737041. DOI: 10.1016/j.ccr.2023.215485.